Cellectis gets green light for non-Hodgkin lymphoma trial

Marginal zone lymphoma

French-headquartered gene-editing biotech company Cellectis says the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). 

The company plans to begin enrolling patients in the NatHaLi-01 study in the second half of the year. 

Enhancing tumor cell killing

“We are delighted that the FDA has cleared our IND application for UCART20x22,” said André Choulika, CEO of Cellectis. 

“This is a very exciting product candidate, for two reasons: UCART20x22 will be our first dual allogeneic CAR T product candidate to enter clinical development, and dual targeting of CD20 and CD22, both validated targets in B-cell malignancies, has the potential to enhance tumor cell killing and increases the breadth of antigen targeting. These advantages may increase the addressable patient population and represent a potential therapeutic alternative to CD19-directed therapies. 

“UCART20x22 is also our first product candidate with fully integrated in-house development, showcasing our transformation into an end-to-end cell and gene therapy company, from discovery, process development, and GMP manufacturing to clinical development. We are very excited to start the clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma.”  

UCART20x22 features TALEN-mediated disruptions of the TRAC gene (that has been shown to reduce the risk of graft-versus-host disease) and of the CD52 gene (to allow using a CD52-directed monoclonal antibody in patients’ preconditioning regimen and enhancing CAR T engraftment, expansion and persistence). 

The Dose Finding portion of the study will evaluate UCART20x22 in a broad range of mature B-cell NHL.

About non-Hodgkin lymphoma

NHL accounts for approximately 4% of all cancers. 

It is estimated that 81,560 new cases of NHL and 20,720 deaths related to the disease occurred in the US in 2021, and 122,979 new cases of NHL and 49,684 deaths related to NHL occurred in Europe in 2020.

About Cellectis

Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. 

Cellectis is developing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its electroporation system, to harness the power of the immune system in order to treat diseases with unmet medical needs. 

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Explore other topics: CancerFrance

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More